Precision Cancer Therapies, Immunologic Approaches for the Treatment of Lymphoid Malignancies (eBook)
496 Seiten
Wiley (Verlag)
978-1-119-82456-5 (ISBN)
Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies
The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science.
Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T).
Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also:
- Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology
- Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms
- Covers FDA-approved drugs and their indications, as well as drugs currently in development
- Provides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy
- Includes boxed sections highlighting major unique points about the information in the chapter
Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.
OWEN A. O'CONNOR, MD, PhD, American Cancer Society Research Professor; Professor of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA.
STEPHEN M. ANSELL, MD, PhD, Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
JOHN G. GRIBBEN, MD, DSc, Hamilton-Fairley Chair of Medical Oncology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK.
Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms Covers FDA-approved drugs and their indications, as well as drugs currently in development Provides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy Includes boxed sections highlighting major unique points about the information in the chapter Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.
List of Contributors
Jeremy S. Abramson
Massachusetts General Hospital and Harvard Medical School
Boston, MA, USA
Stephen M. Ansell
Division of Hematology, Department of Medicine
Mayo Clinic
Rochester, MN, USA
Marie-France Aubin
University Institute for Hematology-Oncology and Cell
Therapy (IHOT) and Centre de recherche de l’Hôpital
Maisonneuve-Rosemont-CIUSSS-EMTL
Université de Montréal
Montréal, Canada
Miriam Barnett
Myeloid Therapeutics
Cambridge, MA, USA
Allison M. Bock
Division of Hematology
Department of Internal Medicine Mayo Clinic
Mayo Clinic Comprehensive Cancer Center
Rochester, MN, USA
Catherine M. Bollard
Center for Cancer and Immunology Research
Children’s National Research Institute
Children’s National Hospital
Washington, DC, USA
Division of Blood and Marrow Transplantation
Children’s National Hospital
Washington, DC, USA
Department of Pediatrics
The George Washington University School of
Medicine and Health Sciences
Washington DC, USA
George Washington Cancer Center
Washington DC, USA
Alessandro Broccoli
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy
Istituto di Ematologia “Seràgnoli,” Dipartimento di Scienze
Mediche e Chirurgiche
Università degli Studi
Bologna, Italy
Ryan Bucktrout
Weill Cornell Medical College
Cornell University
New York, NY, USA
Timothy N. Bullock
Professor of Pathology, School of Medicine
University of Virginia
VA, USA
Jason Yongsheng CHAN
Division of Medical Oncology
National Cancer Centre Singapore, Singapore
Oncology Academic Clinical Program
Duke-NUS Medical School
Singapore
Bruce D. Cheson
Lymphoma Research Foundation
New York, NY, USA
Center for Cancer and Blood Disorders
Bethesda, MD, USA
Máire A. Conrad
Perelman School of Medicine, Division of
Gastroenterology, Hepatology, and Nutrition
The Children’s Hospital of Philadelphia
University of Pennsylvania
Philadelphia, PA, USA
Clifford M. Csizmar
Department of Medicine
Mayo Clinic
Rochester, MN, USA
Jean-Sébastien Delisle
University Institute for Hematology-Oncology and Cell
Therapy (IHOT) and Centre de recherche de l’Hôpital
Maisonneuve-Rosemont-CIUSSS-EMTL
Université de Montréal
Montréal, QC, Canada
Todd A. Fehniger
Stem Cell Biology and Bone Marrow
Transplantation & Leukemia Unit
Oncology Division, Department of Medicine
Washington University School of Medicine
St. Louis, MO, USA
Michele Gerber
Myeloid Therapeutics
Cambridge, MA, USA
Daniel Getts
Myeloid Therapeutics
Cambridge, MA, USA
Nilanjan Ghosh
Levine Cancer Institute Charlotte, NC, USA
Richard C. Godby
Division of Hematology
Department of Internal Medicine Mayo Clinic
Mayo Clinic Comprehensive Cancer Center
Rochester, MN, USA
John G. Gribben
Centre for Haemato-Oncology
Barts Cancer Institute, Queen Mary University of London
London, UK
J.Erika Haydu
Massachusetts General Hospital and Harvard
Medical School
Boston, MA, USA
Miriam T. Jacobs
Stem Cell Biology and Bone Marrow Transplantation & Leukemia Unit
Oncology Division, Department of Medicine
Washington University School of Medicine
St. Louis, MO, USA
Kallesh Danappa Jayappa
Division of Hematology-Oncology
Translational Orphan Blood Cancer Research Center
Program for T-Cell Malignancies, Department of Medicine
University of Virginia Comprehensive Cancer Center
VA, USA
Judith Kelsen
Perelman School of Medicine, Division of Gastroenterology
Hepatology, and Nutrition
The Children’s Hospital of Philadelphia
University of Pennsylvania
Philadelphia, PA, USA
Saad S. Kenderian
Division of Hematology
Department of Internal Medicine Mayo Clinic
Mayo Clinic Comprehensive Cancer Center
Rochester, MN, USA
Nadia Khan
Center for Blood Disorders & Cellular Therapies
Swedish Cancer Institute
Seattle, WA, USA
Seok Jin Kim
Division of Hematology-Oncology
Sungkyunkwan University School of Medicine
Samsung Medical Center, Seoul, Korea
Won Seog Kim
Division of Hematology-Oncology
Sungkyunkwan University School of Medicine
Samsung Medical Center, Seoul, Korea
Hiroshi Kimura
Department of Virology
Nagoya University Graduate
School of Medicine
Nagoya, Japan
Hannah Kinoshita
Center for Cancer and Immunology Research
Children’s National Research Institute
Children’s National Hospital
Washington, DC, USA
Division of Blood and Marrow Transplantation
Children’s National Hospital
Washington, DC, USA
Division of Oncology, Children’s National Hospital
Washington DC, USA
Mithunah Krishnamoorthy
Senior Scientist, Pfizer Inc.
San Diego, CA, USA
Soon Thye LIM
Division of Medical Oncology
National Cancer Centre Singapore
Singapore
Oncology Academic Clinical Program
Duke-NUS Medical School
Singapore
Yi Lin
Division of Hematology
Department of Internal Medicine Mayo Clinic
Mayo Clinic Comprehensive Cancer Center
Rochester, MN, USA
Jennifer K. Lue
Lymphoma Service, Division of Hematological Malignancies
Department of Medicine, Memorial Sloan Kettering Cancer Center
New York, NY, USA
John Sanil Manvalan
Division of Hematology-Oncology
Translational Orphan Blood Cancer Research Center
Program for T-Cell Malignancies, Department of Medicine, University of Virginia Comprehensive Cancer Center
VA, USA
Enrica Marchi
Division of Hematology-Oncology
Translational Orphan Blood Cancer Research Center
Program for T-Cell Malignancies, Department of Medicine
University of Virginia Comprehensive Cancer Center
VA, USA
Nancy D. Marin
Stem Cell Biology and Bone Marrow Transplantation & Leukemia Unit
Oncology Division, Department of Medicine
Washington University School of Medicine
St. Louis, MO, USA
Siddartha Mukherjee
Myeloid Therapeutics
Cambridge, MA, USA
Columbia University
New York, NY, USA
Takayuki Murata
Department of Virology and Parasitology
Fujita Health University School of Medicine
Toyoake, Japan
Swathi Namburi
Center for Blood Disorders & Cellular Therapies
Swedish Cancer Institute
Seattle, WA, USA
Owen A. O’Connor
Division of Hematology-Oncology
Translational Orphan Blood Cancer Research Center
Program for T-Cell Malignancies
Department of Medicine
University of Virginia Comprehensive Cancer Center
VA, USA
Choon Kiyat ONG
Lymphoma Genomic Translational Research Laboratory
Division of Cellular and Molecular Research
National Cancer Centre Singapore
Singapore
Cancer and Stem Cell Biology, Duke-NUS Medical School
Singapore
Andrea Orlando
Weill Cornell Medical College
Cornell University
New York, NY, USA
Colette Owens
Lymphoma Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY, USA
Weill Cornell Medicine
New York, NY, USA
Ipsita Pal
Division of Hematology-Oncology
Translational Orphan Blood Cancer Research Center
Program for T-Cell Malignancies, Department of Medicine
University of Virginia Comprehensive Cancer Center
VA, USA
Krish Patel
Center for Blood Disorders & Cellular Therapies
Swedish Cancer Institute
Seattle, WA, USA
Kevin D. Pavelko
Department of Immunology
Mayo Clinic
Rochester, MN, USA
Immune Monitoring Core Laboratory
Mayo Clinic
Rochester, MN, USA
Barbara Pro
Clinical Director of Lymphoma at the Herbert Irving
Comprehensive Cancer Center, Columbia University
New York, NY, USA
Marc-Anthony Rodriguez
Division of Hematology and Medical Oncology
Department of Medicine, Weill Cornell Medicine
New York, NY, USA
Weill Cornell Medical College
Cornell University
New York, NY, USA
Gilles Salles
Lymphoma Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY, USA
Weill Cornell Medicine
New York, NY, USA
Stephen J. Schuster
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA, USA
Inna Serganova
Weill Cornell Medical College
Cornell University
New York, NY, USA
Eric L. Sievers
Chief Medical Officer
BioAtla, Inc.
San Diego, CA, USA
Sonali M. Smith
Elwood V. Jensen Professor of Medicine
Chief, Section of...
| Erscheint lt. Verlag | 21.2.2024 |
|---|---|
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Allgemeines / Lexika |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| ISBN-10 | 1-119-82456-7 / 1119824567 |
| ISBN-13 | 978-1-119-82456-5 / 9781119824565 |
| Haben Sie eine Frage zum Produkt? |
EPUB (Adobe DRM)Größe: 14,6 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
